Cell-mediated immunity elicited by the blood stage malaria vaccine apical membrane antigen 1 in Malian adults: Results of a Phase I randomized trial
Kirsten E. Lyke(University of Maryland, Baltimore), Marcelo B. Sztein(University of Maryland, Baltimore), Bourèma Kouriba(Centre Pour le Développement des Vaccins-Mali), Christopher V. Plowe(University of Maryland, Baltimore), Issa Diarra(University of Bamako), Abdoulaye K. Koné(University of Bamako), Modibo Daou(University of Bamako), Ogobara K. Doumbo(University of Bamako), Sheetij Dutta(Walter Reed Army Institute of Research), D. Gray Heppner(Dallas VA Medical Center), David E. Lanar(Walter Reed Army Institute of Research)
Cited by 22
Related Papers
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
|New England Journal of Medicine|2020|2.7k
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
|Nature|2020|1.6k
Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine
|Science|2013|783
Serum Levels of the Proinflammatory Cytokines Interleukin-1 Beta (IL-1β), IL-6, IL-8, IL-10, Tumor Necrosis Factor Alpha, and IL-12(p70) in Malian Children with Severe<i>Plasmodium falciparum</i>Malaria and Matched Uncomplicated Malaria or Healthy Controls
|Infection and Immunity|2004|447
Genome-wide and fine-resolution association analysis of malaria in West Africa
|Nature Genetics|2009|393